Lite Strategy, Inc.是一家臨床階段的製藥公司,致力於開發新型和差異化的癌症療法。該公司通過收購有前途的癌症藥物來建立管道,並通過臨床開發、戰略合作夥伴關係以及外包許可或商業化(視情況而定)在項目中創造價值。他們的候選藥物管線包括voruciclib,一種口服細胞周期蛋白依賴性激酶9(CDK9)抑製劑和zandelisib,一種口服、每日一次、選擇性PI3K δ抑製劑,這是一種臨床前候選藥物。
董事
名稱
職位
Justin J. File
Director,Chief Executive Officer and Chief Financial Officer and Secretary
Charles B. Lee
Director
Frederick W. Driscoll
Director
James Flynn
Director
Joshua Riezman
Director
Nicholas R. Glover
Director
股東
名稱
職位
Justin J. File
Director,Chief Executive Officer and Chief Financial Officer and Secretary